The open weekend for Marathon, Bungie’s new multiplayer shooter, is just around the corner. During the Server Slam weekend, ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

A major outage at internet infrastructure firm Cloudflare knocked parts of the internet offline, disrupting access to X, NJ Transit, ChatGPT and other major platforms ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Microsoft has announced the release of SQL Server Management Studio Preview 3, which brings many features, including "initial" support for ARM64. SQL Server Management Studio (SSMS) is the tool of ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Managing SQL Server across hybrid and multi-cloud environments has long posed a challenge for database administrators. With data sprawled across on-premises infrastructure, cloud platforms, and edge ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

At Build 2025, SQL Server 2025 officially entered public preview. As one of the world’s most popular databases, this release continues a decades-long history of innovation with features made for ...